NPH human insulin: does it work in a once-a-day regimen?

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Diabetes mellitus management often involves NPH insulin.
• Transitioning between insulin sources requires careful evaluation of efficacy and safety.
• Semisynthetic human NPH insulin offers a potential alternative to animal-sourced NPH insulin.

Purpose of the Study:

• To evaluate the 24-hour therapeutic effect of semisynthetic human NPH insulin.
• To compare its efficacy and safety against animal-sourced NPH insulin in diabetic patients.
• To assess glycemic control and safety profiles during the transition.

Main Methods:

• A clinical transfer trial involving diabetic patients on once-daily animal NPH insulin.
• Patients were switched to semisynthetic human NPH insulin (Novolin N) at equivalent doses.
• Glycemic control (fasting blood glucose, hemoglobin A1C) and safety (hypoglycemic events, body weight) were monitored over 8 weeks.

Main Results:

• 85% of patients completed the study with minimal insulin dose adjustments.
• No significant changes were observed in mean fasting blood glucose or hemoglobin A1C levels.
• A statistically significant increase in mean body weight was noted (P <= 0.01).
• 74% of patients experienced unchanged or improved glycemic control.
• The frequency of hypoglycemic events remained comparable.

Conclusions:

• Semisynthetic human NPH insulin provides a comparable 24-hour therapeutic effect to animal-sourced NPH insulin.
• The switch to semisynthetic human NPH insulin is generally well-tolerated with stable glycemic control.
• This insulin offers a safe and effective alternative for diabetic patients requiring NPH insulin therapy.